Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy
Authors:
- 17 December 2024
- journal article
- Published by Wiley in Angewandte Chemie
- Vol. 137 (5)
Abstract
Proteolysis‐targeting chimeras (PROTACs) are a promising technique for the specific and durable degradation of cancer‐related proteins via the ubiquitin‐proteasome system in cancer treatment. However, the therapeutic efficacy of PROTACs is restricted due to their hydrophobicity, poor cell permeability and insufficient tumor‐targeting ability. Herein, we develop the self‐assembled peptide‐derived PROTAC nanoparticles (PT‐NPs) for precise and durable programmed death‐ligand 1 (PD−L1) degradation in targeted tumors. The PT‐NPs with an average size of 211.8 nm are formed through the self‐assembly of amphiphilic peptide‐derived PROTAC (CLQKTPKQC‐FF‐ALAPYIP), comprising a PD−L1‐targeting ‘CLQKTPKQC’, self‐assembling linker ‘FF’ and E3 ligase recruiting ‘ALAPYIP’. Particularly, PT‐NPs strongly bind to tumor cell surface PD−L1 to form PD−L1/PT‐NPs complex, then internalized through receptor‐mediated endocytosis and degraded in lysosomes. Second, free PROTACs released from PT‐NPs to the cytoplasm further induce the durable proteolysis of cytoplasmic PD−L1 via the ubiquitin‐proteasome system. In colon tumor models, intravenously injected PT‐NPs accumulate significantly at targeted tumor tissues through nanoparticle‐derived passive and active targeting. At the targeted tumor tissues, PT‐NPs promote durable PD−L1 degradation and ultimately trigger a substantial antitumor immune response. Collectively, this study provides valuable insights into the rational design of self‐assembled peptide‐derived PROTAC nanoparticles to ensure noticeable accuracy and enhanced efficacy in cancer treatment.Keywords
Funding Information
- Ministry of Science and ICT, South Korea (NRF-2022M3H4A1A03067401)
This publication has 54 references indexed in Scilit:
- All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapyBioactive Materials, 2023
- An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancerBioactive Materials, 2022
- Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapyBiomaterials, 2022
- Imaging and quantifying analysis the binding behavior of PD-L1 at molecular resolution by atomic force microscopyAnalytica Chimica Acta, 2022
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast CancerAngewandte Chemie International Edition, 2021
- Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1Acta Pharmaceutica Sinica B, 2020
- Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progressionBiomaterials, 2020
- PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug DiscoveryBioEssays, 2018
- Challenges and strategies in anti-cancer nanomedicine development: An industry perspectiveAdvanced Drug Delivery Reviews, 2017
- Encyclopedia of Polymeric Nanomaterials2015